ACC.18
ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.
AHA 2017 Scientific Sessions
Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.
AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
ESC 2017
This is an investigational use for Eliquis.
AACE 2017
The 28-year-old male patient presented with acute-onset vertigo, nausea, vomiting, and unsteady gait.
ACC.17
The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.
AHA 2015
Older patients, females, and those with comorbidities were more likely to be on multiple medications.
AHA 2015
Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.
